Walgreens Boots Alliance reported Q3 FY2024 sales of $36.4 billion, up 2.6% YoY, while adjusted EPS declined 36.6% to $0.63, impacted by lower sale-leaseback gains and challenging U.S. retail environment. The company lowered its FY2024 adjusted EPS guidance to $2.80-$2.95 due to persistent pharmacy margin pressures and weak consumer spending.The company announced strategic initiatives including optimization of U.S. store footprint, launching retail pharmacy action plan, and simplifying healthcare portfolio. Q3 operating income was $111 million compared to a loss of $477 million last year. U.S. Retail Pharmacy segment saw comparable sales increase of 3.5%, while International segment grew 2.8%.Free cash flow improved to $334 million, up $778 million YoY, driven by working capital optimization and reduced capital expenditures. The U.S. Healthcare segment achieved positive adjusted EBITDA of $23 million, marking second consecutive quarter of profitability improvement.

Walgreens Boots Alliance reported Q3 FY2024 sales of $36.4 billion, up 2.6% YoY, while adjusted EPS declined 36.6% to $0.63, impacted by lower sale-leaseback gains and challenging U.S. retail environment. The company lowered its FY2024 adjusted EPS guidance to $2.80-$2.95 due to persistent pharmacy margin pressures and weak consumer spending.The company announced strategic initiatives including optimization of U.S. store footprint, launching retail pharmacy action plan, and simplifying healthcare portfolio. Q3 operating income was $111 million compared to a loss of $477 million last year. U.S. Retail Pharmacy segment saw comparable sales increase of 3.5%, while International segment grew 2.8%.Free cash flow improved to $334 million, up $778 million YoY, driven by working capital optimization and reduced capital expenditures. The U.S. Healthcare segment achieved positive adjusted EBITDA of $23 million, marking second consecutive quarter of profitability improvement.